Search for: "APOTEX INC. v. SANOFI-AVENTIS"
Results 1 - 20
of 54
Sorted by Relevance
|
Sort by Date
9 Nov 2011, 9:59 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed a decision by the District Court for the Southern District of New York awarding prejudgment interest to Plaintiffs-Appellees Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership ("Sanofi"); affirmed the District Court's denial of a motion for leave to file a supplemental answer, affirmative… [read post]
18 Jan 2015, 9:06 pm
LLC; Aventis Pharma S.A.; Sanofi • Defendants: Apotex Corp.; Apotex Inc. [read post]
19 Jun 2007, 9:45 pm
By Donald Zuhn -- Sanofi-Aventis and Bristol-Myers Squibb announced today (June 19, 2007) that the U.S. [read post]
31 Aug 2006, 6:15 pm
Apotex Inc., 02cv2255, U.S. [read post]
15 Aug 2006, 6:45 am
Sanofi-Aventis SA and Bristol-Myers Squibb filed for a preliminary injunction against Apotex Inc . to stop sales of a generic version of Plavix ® (clopidogrel bisulfate). [read post]
2 Sep 2008, 12:39 am
Sanofi-Aventis et al. v. [read post]
18 Oct 2011, 8:31 am
” Sanofi- Aventis v. [read post]
26 Jan 2007, 6:09 am
In August 2006, generic drug maker Apotex Inc. began selling a cheaper version of Plavix, a blood thinner Bristol-Myers co-markets with Sanofi-Aventis SA, after an agreement to settle a patent dispute fell apart. [read post]
30 Oct 2014, 8:21 am
Apotex Inc., et al. [read post]
26 Jul 2014, 9:14 pm
Methods of medical treatment came under scrutiny of the US Supreme Court in Mayo Collaborative Services v Prometheus Laboratories, Inc and the Australian High Court in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (see High Court Rules Methods of Medical Treatment Patent-Eligible). [read post]
1 Dec 2009, 9:45 am
(patent infringement) 10/29: Aventis Pharma S.A. and Sanofi-Aventis US, LLC v. [read post]
19 Apr 2012, 10:00 pm
The post points out two major caveats in the decision. 4) Patent Docs: Marine Polymer Technologies, Inc. v. [read post]
19 Apr 2012, 10:00 pm
The post points out two major caveats in the decision. 4) Patent Docs: Marine Polymer Technologies, Inc. v. [read post]
25 Jul 2013, 11:43 am
By Dennis Crouch Mylan Inc. v. [read post]
21 Nov 2014, 4:00 am
Justice Gleason found Sanofi-Aventis 2007 was “dispositive” and it was an abuse for the brand to re-litigate obviousness in case2: “That issue was the same in both cases and arose directly from the patent, itself. [read post]
18 Feb 2011, 11:47 am
The defendants in both sets of actions were Sanofi Aventis and Sanofi-Synthelabo, Inc., Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively “Sanofi”) and Apotex Corporation (“Apotex”). [read post]
31 Aug 2010, 10:01 pm
Apotex Inc. et al (Docket Report) Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal? [read post]
23 Jun 2009, 9:46 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Eloxatin (Oxaliplatin) – US: District Court New Jersey grants summary judgment of non-infringement in favour of Hospira, Teva and others concerning patent relating to Sanofi’s Eloxatin: Sanofi-Aventis v Sandoz (SmartBrief) (The IP Factor) (GenericsWeb) (Patents4Life) General Europe’s… [read post]
23 Jun 2010, 10:28 pm
Apotex, Inc. et al. [read post]
10 Aug 2011, 4:30 am
”: a note on Neurim (The SPC blog) France: The end of the reform on the appearance of generic drugs and IPR (Class 46) Spain: A SHED OF LIGHT IN THE DARK: First Spanish decision admitting post-grant claim limitations under article 138.3 of CPE 2000: Sanofi-Aventis v. [read post]
